Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs

Active, not recruitingOBSERVATIONAL
Enrollment

409

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions
Neurofibroma, Plexiform
Trial Locations (25)

Unknown

Research Site, Beijing

Research Site, Chongqing

Research Site, Lanzhou

Research Site, Guangzhou

Research Site, Shenzhen

Research Site, Nanning

Research Site, Guiyang

Research Site, Shijiazhuang

Research Site, Zhengzhou

Research Site, Wuhan

Research Site, Changsha

Research Site, Nanjing

Research Site, Suzhou

Research Site, Nanchang

Research Site, Shenyang

Research Site, Jinan

Research Site, Shanghai

Research Site, Taiyuan

Research Site, Xi’an

Research Site, Chengdu

Research Site, Tianjin

Research Site, Kunming

Research Site, Hangzhou

Research Site, Wenzhou

Research Site, Nanjing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY